NCT06769126 - Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study | Biotech Hunter

Enrollment

900

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions

Extensive Stage Lung Small Cell CarcinomaLung Small Cell Carcinoma, A SubtypeLung Small Cell Carcinoma, I SubtypeLung Small Cell Carcinoma, N SubtypeLung Small Cell Carcinoma, P Subtype

Interventions

PROCEDURE

Biospecimen Collection

Undergo tissue and blood sample collection

DRUG

Ceralasertib

Given PO

PROCEDURE

Computed Tomography

Undergo CT scan

BIOLOGICAL

Durvalumab

Given IV

DRUG

Etoposide

Given etoposide

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Monalizumab

Given IV

DRUG

Platinum Compound

Given platinum compound

PROCEDURE

Positron Emission Tomography

Undergo PET/CT scan

DRUG

Saruparib

Given PO

RADIATION

Thoracic Radiation Therapy

Undergo thoracic radiation

Trial Locations (7)

52403

RECRUITING

Mercy Hospital, Cedar Rapids

RECRUITING

Oncology Associates at Mercy Medical Center, Cedar Rapids

59101

RECRUITING

Billings Clinic Cancer Center, Billings

59804

RECRUITING

Community Medical Center, Missoula

83814

RECRUITING

Kootenai Health - Coeur d'Alene, Coeur d'Alene

83854

RECRUITING

Kootenai Clinic Cancer Services - Post Falls, Post Falls

83864

RECRUITING

Kootenai Clinic Cancer Services - Sandpoint, Sandpoint

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

SWOG Cancer Research Network

NETWORK